← Back to Experts
Li Benshang

Li Benshang

Chief Physician; Doctoral Supervisor

Innovation Diagnosis and Treatment Center, Ward 1

Shanghai Children's Medical Center International Department

The official SCMC page presents Li Benshang as a senior specialist focused on pediatric CAR-T and related cell therapies for relapsed or refractory leukemia, lymphoma, and solid tumors.

Biography

According to the official page, Li Benshang is a chief physician and doctoral supervisor in SCMC's Innovation Diagnosis and Treatment Center, Ward 1, and also directs the Cell Preparation Center. The page states that he was among the early domestic pioneers in basic and clinical cell-therapy research for relapsed or refractory pediatric acute leukemia, lymphoma, and solid tumors, and that he has participated in more than 1,000 related clinical cases. It also lists multiple academic leadership roles and overseas study or exchange at St. Jude Children's Research Hospital and the University of Hamburg.

Specialties

Pediatric CAR-T cell immunotherapy
Relapsed or refractory acute leukemia
Lymphoma
Pediatric solid tumors
Cell therapy exploration for autoimmune disease

Practice Areas

  • Pediatric hematology-oncology
  • Cell therapy
  • Immunotherapy
  • Translational medicine

Conditions Treated

Relapsed acute leukemia
Refractory leukemia
Lymphoma
Pediatric solid tumors
Selected autoimmune diseases

Academic Titles

  • Doctoral Supervisor
  • Director of the Cell Preparation Center
  • Visiting Professor at the Shanghai Institute of Hematology

Education & Overseas Experience

The reviewed official page specifically notes study or exchange at St. Jude Children's Research Hospital in the United States and the University of Hamburg in Germany. A full formal education chronology is not clearly provided in the excerpt reviewed.

Signature Techniques

  • Pediatric CAR-T cell therapy
  • Cell preparation and translational cell-therapy programs

International Patient Fit

Potentially relevant for international families seeking advanced cell therapy or CAR-T options for relapsed or refractory pediatric blood cancers or tumors. The reviewed page suggests strong translational expertise but does not explicitly outline foreign-language support or international patient workflows.

Achievements

  • Participated in 1,000+ related clinical cases
  • Among early domestic pioneers in pediatric CAR-T and cell therapy research

Credentials

  • Chief Physician
  • Doctoral Supervisor
  • Director of the Cell Preparation Center

Languages

Chinese

Related Conditions

Related Treatments